Posted by Michael Wonder on 02 May 2026
Arrowhead Pharmaceuticals receives TGA approval of Redemplo (plozasiran) in Australia, expanding global access for patients with familial chylomicronaemia syndrome
1 May 2026 - The approval in Australia is based on positive results from the Phase 3 PALISADE study where Redemplo reduced triglycerides by a median of 80% from baseline and significantly reduced the incidence of acute pancreatitis across pooled doses, as compared with those using placebo
Arrowhead Pharmaceuticals today announced that the Australian TGA has approved Redemplo (plozasiran), a small interfering RNA medicine, as an adjunct to diet to reduce triglyceride levels for adult patients with familial chylomicronaemia syndrome for whom standard triglyceride lowering therapies have been inadequate.
